These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 18161123

  • 21. [Osteoporosis and bisphosphonates].
    Zuber MA.
    Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
    [No Abstract] [Full Text] [Related]

  • 22. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
    MMW Fortschr Med; 2006 Jun 22; 148(25):60-1. PubMed ID: 16859169
    [No Abstract] [Full Text] [Related]

  • 23. Fracture risk associated with chronic use of bisphosphonates: evidence today.
    Charopoulos I, Orme S, Giannoudis PV.
    Expert Opin Drug Saf; 2011 Jan 22; 10(1):67-76. PubMed ID: 21121870
    [Abstract] [Full Text] [Related]

  • 24. Femoral fractures in osteoporotic patients on bisphosphonates. A case report.
    Alshahrani F, Kendler D.
    J Clin Densitom; 2012 Jan 22; 15(3):380-4. PubMed ID: 22572530
    [Abstract] [Full Text] [Related]

  • 25. [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
    Kishimoto H.
    Clin Calcium; 2008 Oct 22; 18(10):1417-26. PubMed ID: 18830038
    [Abstract] [Full Text] [Related]

  • 26. What is the optimal duration of bisphosphonate therapy?
    Ott SM.
    Cleve Clin J Med; 2011 Sep 22; 78(9):619-30. PubMed ID: 21885695
    [Abstract] [Full Text] [Related]

  • 27. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.
    Anastasilakis AD, Goulis DG, Kita M, Avramidis A.
    Hormones (Athens); 2007 Sep 22; 6(3):233-41. PubMed ID: 17724008
    [Abstract] [Full Text] [Related]

  • 28. Intravenous bisphosphonates in osteoporosis and jaw osteonecrosis: comment on the article by Delmas et al.
    Landis BN, Hugentobler M.
    Arthritis Rheum; 2006 Nov 22; 54(11):3720-1; author reply 3721-2. PubMed ID: 17075888
    [No Abstract] [Full Text] [Related]

  • 29. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
    Ringe JD.
    MMW Fortschr Med; 2009 Mar 05; 151(10):7. PubMed ID: 19472655
    [No Abstract] [Full Text] [Related]

  • 30. Unusual mid-shaft fractures during long-term bisphosphonate therapy.
    Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS.
    Clin Endocrinol (Oxf); 2010 Feb 05; 72(2):161-8. PubMed ID: 19302584
    [Abstract] [Full Text] [Related]

  • 31. [Osteoporosis therapy. Bisphosphonates compared].
    MMW Fortschr Med; 2003 Mar 27; 145(13):60. PubMed ID: 15101545
    [No Abstract] [Full Text] [Related]

  • 32. Corticosteroids: no drug prevention of fractures needed.
    Prescrire Int; 2009 Aug 27; 18(102):175. PubMed ID: 19746563
    [Abstract] [Full Text] [Related]

  • 33. [Evidence and utility of etidronate for the treatment of osteoporosis].
    Takada J, Iba K, Yamashita T, Yoshizaki T.
    Clin Calcium; 2008 Oct 27; 18(10):1427-33. PubMed ID: 18830039
    [Abstract] [Full Text] [Related]

  • 34. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
    Okazaki R.
    Clin Calcium; 2009 Jan 27; 19(1):30-6. PubMed ID: 19122262
    [Abstract] [Full Text] [Related]

  • 35. [Alendronate for treatment of osteoporoses].
    Harada A.
    Nihon Rinsho; 2009 May 27; 67(5):943-7. PubMed ID: 19432114
    [Abstract] [Full Text] [Related]

  • 36. [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].
    Hosoi T.
    Clin Calcium; 2009 Jan 27; 19(1):11-8. PubMed ID: 19122260
    [Abstract] [Full Text] [Related]

  • 37. Study finds no link between bone drugs and unusual thigh fractures.
    Harv Womens Health Watch; 2010 Jul 27; 17(11):6. PubMed ID: 20684079
    [No Abstract] [Full Text] [Related]

  • 38. [Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
    Asano S, Suzuki A, Itoh M.
    Clin Calcium; 2009 Aug 27; 19(8):1179-85. PubMed ID: 19638702
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct 27; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 40. Bisphosphonates and bone...what have we learned?
    Guttenberg SA.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec 27; 106(6):769-72. PubMed ID: 18835534
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.